CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens

Journal of Leukocyte Biology

Volumn 69, Issue 1, 2001, Pages 81-88

  Jahrsdörfer, Bernd ^a   Hartmann, Gunther ^a   Racila, Emil ^c   Jackson, Wallen ^b   Mühlenhoff, Lars ^a   Meinhardt, Gerold ^a   Endres, Stefan ^a   Link, Brian K ^b,c,d   Krieg, Arthur M ^b,c,d   Weiner, George J ^b,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d PFIZER INC   (United States)

Author keywords

B cell activation; CLL; Follicular hyperplasia; Monoclonal antibodies; Non Hodgkin lymphoma; ODN

Indexed keywords

B7 ANTIGEN; BACTERIAL DNA; CD20 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; DINUCLEOTIDE; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; OLIGODEOXYNUCLEOTIDE;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LEUKEMIA; LYMPHOMA; NONHODGKIN LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL;

ANTIGEN PRESENTATION; ANTIGENS, CD; B-LYMPHOCYTES; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; OLIGODEOXYRIBONUCLEOTIDES; TUMOR CELLS, CULTURED;

BACTERIA (MICROORGANISMS);

EID: 0035155134     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells
2. Regulation of survival in normal and neoplastic B lymphocytes
3. Signals for survival and apoptosis in normal and neoplastic B lymphocytes
4. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas
5. T cell mediated immunotherapy for B cell lymphoma
6. Preclinical and phase I and II trials of rituximab
7. Rituximab in indolent lymphoma: The single-agent pivotal trial
8. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
9. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
10. Clinical status and optimal use of rituximab for B cell lymphomas
11. Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors
12. Inhibition of human B cell lymphoma growth CD40 stimulation
13. Negative signaling in B cells by surface imnmunoglobulins
14. Mechanisms involved in the inhibition of growth of a human B lymphoma cell line. B104, by anti-MHC class II antibodies
15. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor
16. Production and characterization of a bispecific IgG capable of inducing T cell-mediated lysis of malignant B cells
17. Anti-CD3-based bispecific antibody designed for therapy of human B cell malignancy can induce T cell activation by antigen-dependent and antigen-independent mechanisms
18. Mechanisms and therapeutic applications of immune stimulatory CpG DNA
19. Mechanism of action of CpG DNA
20. Bacterial CpG DNA activates immune cells to signal infectious danger
21. CpG oligodexynucleotides act as adjuvants that switch on T helper I (Th1) immunity
22. Immunostimulatory oligodeoxynucleotides containing the CpG- motif are effective as immune adjuvants in tumor antigen immunization
23. Immunostimulatory DNA sequences function as T helper-I-promoting adjuvants
24. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants
25. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
26. Mechanism and function of a newly identified CpG DNA motif in human primary B cells
27. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells
28. Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes
29. Determination of lymphocyte division by flow cytometry
30. Detection of apoptosis and DNA replication by differential labeling of DNA strand break with fluorochromes of different color
31. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
32. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma
33. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle cell lymphoma, immunocytoma, and small B cell lymphocytic lymphoma
34. Phase 1/11 trial of IDEC-Y2B8 radioimmunotherapy, for treatment of relapsed or refractory CD20(+) B cell non-Hodgkin's lymphoma
35. Single-agent monoclonal antibody efficacy in bulky non-Hodkin's lymphoma: Results of a phase II trial of rituximab
36. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
37. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
38. Levels of expression of CD19 and CD20 in chronic B cell leukaemias
39. Therapy of B cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
40. CD20-negative relapse in B-cell lymphoma after treatment with rituximab
41. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA
42. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation
43. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
44. CpG DNA and LPS induce distinct patterns of activation in human monocytes
45. CpG-oligodeoxynucleotides enhance T cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12
46. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses